143 related articles for article (PubMed ID: 26427518)
1. A critical appraisal of the selegiline transdermal system for major depressive disorder.
Bied AM; Kim J; Schwartz TL
Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
[TBL] [Abstract][Full Text] [Related]
2. Selegiline transdermal system: a novel treatment option for major depressive disorder.
Nandagopal JJ; DelBello MP
Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
[TBL] [Abstract][Full Text] [Related]
3. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
4. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
6. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
7. Transdermal selegiline.
Patkar AA; Pae CU; Zarzar M
Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
[TBL] [Abstract][Full Text] [Related]
8. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Robinson DS; Amsterdam JD
J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
[TBL] [Abstract][Full Text] [Related]
9. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin M
Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase inhibitors: a new generation.
Robinson DS
Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
[TBL] [Abstract][Full Text] [Related]
12. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
13. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Patkar AA; Pae CU; Masand PS
CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
DelBello MP; Hochadel TJ; Portland KB; Azzaro AJ; Katic A; Khan A; Emslie G
J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):311-7. PubMed ID: 24955812
[TBL] [Abstract][Full Text] [Related]
15. Selegiline transdermal system Somerset.
Mahmood I
Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
[TBL] [Abstract][Full Text] [Related]
16. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
[TBL] [Abstract][Full Text] [Related]
17. Critical appraisal of selegiline transdermal system for major depressive disorder.
Cristancho MA; Thase ME
Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935
[TBL] [Abstract][Full Text] [Related]
18. Selegiline transdermal system: in the treatment of major depressive disorder.
Frampton JE; Plosker GL
Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
[TBL] [Abstract][Full Text] [Related]
19. Selegiline transdermal system: current awareness and promise.
Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
[TBL] [Abstract][Full Text] [Related]
20. MAO inhibitors: risks, benefits, and lore.
Wimbiscus M; Kostenko O; Malone D
Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
